Gene therapy of hepatocellular carcinoma

Digestive Diseases

Volumn 19, Issue 4, 2001, Pages 324-332

  Ruiz, Juan ^a   Mazzolini, Guillermo ^a   Sangro, Bruno ^a   Qian, Cheng ^a   Prieto, Jesús ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

Author keywords

Fetoprotein; Adenoviruses; Clinical trial; Dendritic cells; Endostatin; Interleukin 12; Liposomes; p53; Retroviruses; Thymidine kinase

Indexed keywords

ADENOVIRUS VECTOR; ALPHA FETOPROTEIN; CYTOKINE; FLUCYTOSINE; GANCICLOVIR; INTERLEUKIN 12; NITROREDUCTASE; ONCOLYTIC VIRUS; PROTEIN BCL 2; PROTEIN P53; RECOMBINANT DNA; THYMIDINE KINASE;

ADENOVIRUS; CANCER CELL CULTURE; CLINICAL TRIAL; CYTOTOXICITY; DNA VECTOR; ENZYME ACTIVITY; GENE ACTIVATION; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; HERPES SIMPLEX VIRUS; HUMAN; IMMUNOGENICITY; LIVER CELL CARCINOMA; NONHUMAN; ONCOGENE; PHENOTYPE; PRIORITY JOURNAL; RETROVIRUS; REVIEW; STROMA CELL; SUICIDE GENE THERAPY; SUPPRESSOR GENE; TRANSGENE; TUMOR CELL; VIRUS INFECTIVITY;

ANIMALS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIALS; DISEASE MODELS, ANIMAL; GENE THERAPY; GENES, TUMOR SUPPRESSOR; GENETIC VECTORS; HUMANS; LIVER NEOPLASMS; ONCOGENES; PHENOTYPE;

EID: 0035729050     PISSN: 02572753     EISSN: None     Source Type: Journal    
DOI: 10.1159/000050699     Document Type: Review

References (74)

1. Hepatocellular carcinoma
2. Nonsurgical treatment of hepatocellular carcinoma
3. The basic science of gene therapy
4. Gene therapy for cancer
5. Researchers and regulators reflect on first gene therapy death
6. Complete cure of established murine hepatocellular carcinoma is achievable by repeated injections of retroviruses carrying the herpes simplex virus thymidine kinase gene
7. Transduction of hepatocellular carcinoma (HCC) using recombinant adeno-associated virus (AAV): In vitro and in vivo effects of genotoxic agents
8. Oncolysis of diffuse hepatocellular carcinoma by intravascular administration of a replication-competent genetically engineered herpesvirus
9. Cancer gene therapy by adenovirus-mediated gene transfer
10. Pre-existing immunity to adenovirus does not prevent tumor regression following intratumoral administration of a vector expressing IL-12 but inhibits virus dissemination
11. Key issues in non-viral gene delivery
12. Cationic liposome-mediated gene delivery to the liver and to hepatocellular carcinomas in mice
13. HVJ-liposome-mediated transfection of HSVtk gene driven by AFP promoter inhibits hepatic tumor growth of hepatocellular carcinoma in SCID mice
14. Electro-poration-mediated interleukin-12 gene therapy for hepatocellular carcinoma in the mice model
15. A blood-tumor barrier limits gene transfer to experimental liver cancer: The effect of vasoactive compounds
16. Drug sensitivity ('suicide') genes for selective cancer chemotherapy
17. Differential ganciclovir-mediated cytotoxicity and bystander killing in human colon carcinoma cell lines expressing herpes simplex virus thymidine kinase
18. The extent of heterocellular communication mediated by gap junctions is predictive of bystander tumor cytotoxicity in vitro
19. Induction of sensitivity to ganciclovir in human hepatocellular carcinoma cells by adenovirus-mediated gene transfer of herpes simplex virus thymidine kinase
20. In vivo evidence that metabolic cooperation is responsible for the bystander effect observed with HSV tk retroviral gene therapy
21. Suicide gene therapy of chemically induced mammary tumor in rat: Efficacy and distant bystander effect
22. Generation of an antitumor immune response in a non-immunogenic tumor: HSVtk killing in vivo stimulates a mononuclear cell infiltrate and a Th1-like profile of intratumoral cytokine expression
23. Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression
24. Combined gene therapy with suicide gene and interleukin-12 is more efficient than therapy with one gene alone in a murine model of hepatocellular carcinoma
25. Evaluation of prodrugs ability to induce effective ablation of cells transduced with viral thymidine kinase gene
26. Gene transfer and therapy with adenoviral vector in rats with diethyl-nitrosamine-induced hepatocellular carcinoma
27. Transduction efficacy, antitumoral effect and toxicity of adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir therapy of hepatocellular carcinoma: The woodchuck animal model
28. Evaluation of HSV-tk gene therapy in a rat model of chemically induced hepatocellular carcinoma by intratumoral and intrahepatic artery routes
29. Enzyme prodrug gene therapy: Synergistic use of the herpes simplex virus-cellular thymidine kinase/ganciclovir system and thymidylate synthase inhibitors for the treatment of colon cancer
30. Two-drug combinations that increase apoptosis and modulate bak and bcl-X(L) expression in human colon tumor cell lines transduced with herpes simplex virus thymidine kinase
31. Retrovirus-mediated herpes simplex virus thymidine kinase gene transduction renders human thyroid carcinoma cell lines sensitive to ganciclovir and radiation in vitro and in vivo
32. Prodrug activation gene therapy and external beam irradiation in the treatment of prostate cancer
33. Connexins are expressed in primary brain tumors and enhance the bystander effect in gene therapy
34. Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: Results of a phase I clinical trial in malignant mesothelioma
35. Thymidine kinase gene therapy for human malignant glioma, using replication-deficient retroviruses or adenoviruses
36. In situ gene therapy for adenocarcinoma of the prostate: A phase I clinical trial
37. A phase I/II dose-escalation study of herpes simplex virus type 1 thymidine kinase 'suicide' gene therapy for metastatic melanoma
38. Intratumoral adenovirus-mediated suicide gene transfer for hepatic metastases from colorectal adenocarcinoma: Results of a phase I clinical trial
39. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours
40. Inhibition of cytotoxic T cell development by transforming growth factor β and reversal by recombinant tumor necrosis factor α
41. Costimulation of T cells for tumor immunity
42. Lymphocyte apoptosis induced by CD95 (APO-1/FAS) ligand-expressing tumor cells - A mechanisms of immune evasion?
43. Cytokine gene transfer in tumor inhibition and tumor therapy: Where are we now?
44. Gene transfer to liver cancer cells of B7-1 plus interleukin-12 changes immunoeffector mechanisms and suppresses helper T cell type 1 cytokine production induced by interleukin 12 alone
45. Gene therapy for hepatocellular carcinoma: Long-term remission of primary and metastatic tumors in mice by interleukin-2 gene therapy in vivo
46. Gene therapy of orthotopic hepatocellular carcinoma in rats using adenovirus, coding for interleukin 12
47. Complete regression of established murine hepatocellular carcinoma by in vivo tumor necrosis factor alpha gene transfer
48. Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10
49. Large nontransplanted hepatocellular carcinoma in woodchucks: Treatment with adenovirus-mediated delivery of interleukin 12/B7.1 genes
50. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4
51. B7-1 (CD80)-gene transfer combined with interleukin-12 administration elicits protective and therapeutic immunity against mouse hepatocellular carcinoma
52. Adenovirus-mediated CD40 ligand gene therapy in a rat model of orthotopic hepatocellular carcinoma
53. Adoptive immunotherapy with lymphokine-activated killer cells plus recombinant interleukin 2 in patients with unresectable hepatocellular carcinoma
54. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: A randomised trial
55. Adenoviral gene transfer of IL-12 into tumors synergizes with adoptive T-cell therapy both at the induction and the effector level
56. Dendritic cells and the control of the immunity
57. Feeding dendritic cells with tumor antigens: Self-service buffet or a la carte?
58. Immunotherapy with dendritic cells directed against tumor antigens shared with normal host cells results in severe autoimmune disease
59. Intratumoral injection of bone-marrow derived dendritic cells engineered to produce interleukin-12 induces complete regression of established murine transplantable colon adenocarcinomas
60. Induction of systemic and therapeutic antitumor immunity using intratumoral injection of dendritic cells genetically modified to express interleukin 12
61. Alpha-fetoprotein-specific genetic immunotherapy for hepatocellular carcinoma
62. Blood vessel formation: What is its molecular basis?
63. The growth inhibition of hepatoma by gene transfer of antisense vascular endothelial growth factor
64. A role for interferon-inducible protein 10 in inhibition of angiogenesis by interleukin-12
65. Mutations of p53 gene in hepatocellular carcinoma: Roles of hepatitis B virus and aflatoxin contamination in the diet
66. p53 gene therapy in a rat model of hepatocellular carcinoma: Intra-arterial delivery of a recombinant adenovirus
67. Haras mutations in N-nitrosomorpholine-induced lesions and inhibition of hepatocarcinogenesis by antisense sequences in rat liver
68. In vivo electropo-retic transfer of bcl-2 antisense oligonucleotide inhibits the development of hepatocellular carcinoma in rats
69. Transfer of bcl-xs plasmid is effective in preventing and inhibiting rat hepatocellular carcinoma induced by N-nitrosomorpholine
70. Transduction of antisense cyclin D1 using two-step gene transfer inhibits the growth of rat hepatoma cells
71. Target gene therapy for alpha-fetoprotein-producing hepatocellular carcinoma by E1B55k-attenuated adenovirus
72. Preliminary report: The short-term effects of direct p53 DNA injection in primary hepatocellular carcinomas
73. Intra-arterial p53 gene therapy of liver malignancies: Preclinical studies and initial clinical observations
74. E1B-deleted adenovirus (dl520) gene therapy for patients with primary and secondary liver tumors